Harwood Feffer LLP Announces Investigation of Provectus Biopharmaceuticals, Inc.
May 28, 2014
NEW YORK, May 28, 2014 /PRNewswire/ -- Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against Provectus Biopharmaceuticals, Inc. ("Provectus" or the "Company") (NYSE MKT: PVCT) and its board of directors concerning whether the board has breached its fiduciary duties to shareholders or violated the federal securities laws.
A class action was recently filed against the Company in the United States District Court for the Middle District of Tennessee, Case No. 14-cv-01231, alleging the Company issued numerous misleading and inaccurate public statements in connection with a product candidate called PV-10. According to the complaint, the Company's statements since at least the beginning of 2014 overstated the potential for success of PV-10 while Provectus was simultaneously engaged in improper stock promotion activities.
Our investigation concerns whether the Company's officers and directors should be liable for the harm to Provectus. If you own Provectus shares and wish to discuss this matter with us, or have any questions concerning your rights and interests with regard to this matter, please contact:
Robert I. Harwood, Esq.
Benjamin I. Sachs-Michaels, Esq.
Harwood Feffer LLP
488 Madison Avenue
New York, New York 10022
Phone Numbers: (877) 935-7400
(212)935-7400
Email: bsachsmichaels@hfesq.com
Website: http://www.hfesq.com
Harwood Feffer has been representing individual and institutional investors for many years, serving as lead counsel in numerous cases in federal and state courts. Please visit the Harwood Feffer LLP website (http://www.hfesq.com) for more information about the firm.
Attorney Advertising. © 2014 Harwood Feffer LLP. The law firm responsible for this advertisement is Harwood Feffer LLP (www.hfesq.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Logo - http://photos.prnewswire.com/prnh/20120215/MM54604LOGO
SOURCE Harwood Feffer LLP